Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue (2017 - 2022)

Historic Current Deferred Revenue for Summit Therapeutics (SMMT) over the last 6 years, with Q2 2022 value amounting to $3.2 million.

  • Summit Therapeutics' Current Deferred Revenue fell 5474.79% to $3.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $3.2 million, marking a year-over-year decrease of 5474.79%. This contributed to the annual value of $7.9 million for FY2021, which is 1118.69% down from last year.
  • Per Summit Therapeutics' latest filing, its Current Deferred Revenue stood at $3.2 million for Q2 2022, which was down 5474.79% from $5.1 million recorded in Q1 2022.
  • Summit Therapeutics' 5-year Current Deferred Revenue high stood at $8.9 million for Q4 2020, and its period low was -$35.9 million during Q2 2018.
  • Over the past 5 years, Summit Therapeutics' median Current Deferred Revenue value was -$962358.6 (recorded in 2019), while the average stood at -$1.9 million.
  • As far as peak fluctuations go, Summit Therapeutics' Current Deferred Revenue crashed by 39827.07% in 2018, and later soared by 71201.57% in 2020.
  • Quarter analysis of 5 years shows Summit Therapeutics' Current Deferred Revenue stood at -$8.0 million in 2018, then surged by 81.79% to -$1.5 million in 2019, then surged by 712.02% to $8.9 million in 2020, then dropped by 11.19% to $7.9 million in 2021, then tumbled by 59.3% to $3.2 million in 2022.
  • Its Current Deferred Revenue was $3.2 million in Q2 2022, compared to $5.1 million in Q1 2022 and $7.9 million in Q4 2021.